Agent Skills
› brycewang-stanford/Awesome-Journal-Skills
› journal-of-allergy-and-clinical-immunology
journal-of-allergy-and-clinical-immunology
GitHub辅助评估过敏、哮喘及临床免疫学研究是否适合投稿至JACI期刊。涵盖选题匹配度、证据标准、报告规范（如CONSORT/PRISMA）、注册要求及拒稿风险，仅作投稿定位参考，非临床建议。
Trigger Scenarios
作者指定将过敏或免疫学研究投稿至JACI并寻求匹配度检查
需要将研究重新聚焦于过敏性疾病机制或具有人类相关性的临床实践问题
在JACI、综合医学期刊或基础免疫学期刊之间进行选刊决策
需要确认该期刊对过敏免疫学研究的报告指南、注册及desk-reject预期
Install
npx skills add brycewang-stanford/Awesome-Journal-Skills --skill journal-of-allergy-and-clinical-immunology -g -y
SKILL.md
Frontmatter
{
"name": "journal-of-allergy-and-clinical-immunology",
"description": "Use when targeting The Journal of Allergy and Clinical Immunology (JACI) or deciding whether an allergy\/asthma\/clinical-immunology study fits this venue. Encodes the journal's fit, the clinical-and-mechanistic immunology evidence bar, reporting-guideline and registration requirements, AAAAI\/Elsevier house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice."
}
The Journal of Allergy and Clinical Immunology (journal-of-allergy-and-clinical-immunology)
Journal positioning
The Journal of Allergy and Clinical Immunology (JACI) is the flagship journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), publishing clinical and mechanistic/translational research across allergy, asthma, and clinical immunology — atopic and respiratory allergic disease, food and drug allergy, urticaria, eosinophilic disorders, immunodeficiency, and the type 2 and broader immune mechanisms underlying these conditions. It serves allergists/immunologists and translational immunology scientists, and expects work that either changes allergy/asthma practice or delivers a clear, human-relevant immunologic mechanism; purely descriptive case series and bench studies with no allergic-disease anchor are a weak fit. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JACI author instructions.
When to trigger
- The author names JACI for an allergy, asthma, or clinical-immunology study and wants a fit/framing check.
- A study must be re-framed around an allergic-disease mechanism or a practice-relevant allergy/asthma question with human relevance.
- The author is choosing between JACI, a general-medicine or respiratory journal, and a basic-immunology venue.
- The author needs the journal's reporting-guideline, registration, and desk-reject expectations for allergy/immunology research.
Scope & topic fit
- Asthma and allergic airway disease: phenotyping/endotyping, biologics, and type 2 inflammation mechanisms and trials.
- Food, drug, and venom allergy: diagnosis, oral immunotherapy and desensitization, and tolerance mechanisms.
- Atopic dermatitis, chronic urticaria, and other allergic skin disease — clinical and immunologic studies.
- Eosinophilic disorders, mast-cell disease, and rhinitis/rhinosinusitis with mechanistic or therapeutic advance.
- Primary and secondary immunodeficiency and immune dysregulation with clinical-immunology relevance.
- Translational immunology of allergic/immune disease (cytokine biology, barrier function, omics, immune cell profiling) anchored to human disease.
Method & evidence bar
- Clinical studies must be adequately powered with prespecified, patient-centered endpoints; biomarker/endotype endpoints need validation and justification.
- The applicable reporting guideline must be followed and its checklist supplied: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for diagnostic studies.
- Interventional and immunotherapy trials require prospective registration; the registration number and protocol/statistical-analysis plan are expected.
- Mechanistic/translational claims need rigorous controls, adequate replication, and validation in human samples or disease-relevant models, with appropriate immune-assay rigor (gating, isotype controls, quantification).
- Diagnostic and biomarker claims (e.g., allergy tests, endotype markers) require an independent validation cohort and an accepted reference standard.
- Observational and cohort analyses must address confounding, atopic comorbidity, and missing data; causal language must match the design.
Structure & house style
- AAAAI/Elsevier format with a structured abstract and a concise clinical-implication/capsule summary where required; re-check current article types and limits on the live guide.
- The introduction frames a focused allergy/immunology question and its mechanistic or clinical importance; the discussion states the practice or mechanistic implication plainly.
- Figures must include the controls, replication, and quantification supporting each immunologic claim; CONSORT/STROBE/PRISMA flow diagrams are expected where applicable.
- Supplements carry the protocol, full immunologic methods and reagent details, and additional cohorts/analyses.
Official-submission checklist
- Before giving submission-ready advice, read
../../resources/source-basis.mdand../../resources/official-source-map.md; start from the ICMJE/EQUATOR and AAAAI anchors, then cite the current JACI page you checked. - Search the live site for "Journal of Allergy and Clinical Immunology guide for authors" and follow the current AAAAI/Elsevier version.
- Re-check article types, word/figure limits, structured-abstract and capsule-summary format, and statistical/immune-assay reporting requirements.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD), data-sharing statement, and protocol/SAP submission.
- Re-check IRB/ethics and consent, animal-use approval where relevant, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions win.
Pre-submission self-check
- The study answers a focused allergy/immunology question with a clear mechanistic or practice implication and human relevance.
- Clinical endpoints are prespecified and patient-centered; biomarker/endotype endpoints are validated.
- Mechanistic claims rest on adequately controlled, replicated immune assays, ideally validated in human samples.
- The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
- Immunotherapy/interventional trials are prospectively registered with the number in the manuscript; protocol/SAP provided.
- IRB/consent, ICMJE disclosures, and a data-sharing statement are prepared.
Common desk-reject triggers
- Descriptive case series or cohort slices with no mechanistic or practice advance.
- Mechanistic claims from a single model or cell line with no human validation and weak immune-assay controls.
- Biomarker/diagnostic studies without an independent validation cohort or reference standard.
- Missing trial/immunotherapy registration, protocol, or the required reporting checklist.
- Observational analyses with inadequate confounding/comorbidity handling or overstated causal claims.
- Basic immunology with no allergic-disease anchor, better served by a dedicated immunology venue.
Re-routing decision
- Respiratory-medicine emphasis where asthma/airway outcome dominates over allergy mechanism →
the-lancet-respiratory-medicine. - Rheumatology/autoimmune musculoskeletal focus →
arthritis-and-rheumatology. - Practice-changing, broadly significant trial → general medicine (
jama/ NEJM / The Lancet in the natural-science bundle). - Pure basic immunology with no allergic-disease translation → a basic-science immunology venue in the natural-science bundle.
- Dermatology-dominant atopic disease with no immune mechanism → a specialty dermatology venue.
Output format
[Fit] High / Medium / Low (one-line reason)
[Target] The Journal of Allergy and Clinical Immunology (AAAAI)
[Allergy/immunology tags] <2–3 closest topics, e.g. asthma biologic, food OIT, type 2 inflammation>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD / mechanistic>
[Method/evidence] <power, endpoint/biomarker validity, human validation, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
Version History
- 1839142 Current 2026-07-05 12:36
